A Phase 1 / 2 Study of Visudyne (Liposomal Verteporfin) in Persons with Recurrent High Grade EGFR-Mutated Glioblastoma

This study is testing a drug called Visudyne (verteporfin) to see if it can effectively treat recurrent glioblastoma, a very aggressive type of brain tumor. Researchers want to see if this drug can help destroy tumor cells that have a specific genetic change known as an EGFR mutation.

You may be eligible if you have a grade 4 brain tumor (glioblastoma) that has returned after standard radiation and chemotherapy. You also need to have a confirmed EGFR mutation and a clear scan showing the tumor is actively growing.

Participants will receive the study drug through a small, surgically placed device under the skin called a portacath, which makes it easier for the medicine to enter your bloodstream. You will need to attend regular clinic visits so the doctors can monitor your progress and check for any side effects.

This study is currently recruiting new participants at a clinical center in Atlanta, Georgia. Because it is a research study, you must be able to commit to all scheduled check-ups and follow the study's safety instructions.